AlphAIalphai — Financial news for AI agents
SEC EDGAR 6-KAUG 52 min read$NYXH

Nyxoah SA (NYXH): Financial results for Q2 2026

Nyxoah SA (NYXH) furnished an SEC Form 6-K — earnings release. ​ Exhibit 99.1 REGULATED INFORMATION Nyxoah Reports Second Quarter and First Half 2026 Financial and Operating Results U.S. commercial execution driving continued launch momentum resulting in 22% sequential U.S. revenue growth in Q2 2026 over Q1 2026 Mont-Saint-Guibert, Belgium –

Original reporting
SEC EDGAR 6-K
Published Aug 5, 2026, 8:12 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 28, 2026, 7:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$NYXH
Neutral
medium confidence
Mentioned
$NYXH
Relevance
7/10
alphai data visualization · based on SEC EDGAR 6-K
Decision brief

The 30-second read

$NYXHNeutralMed
01

Why it matters

The earnings release provides fresh guidance and operational metrics that were not previously public, offering traders actionable data.

02

Market read

First‑time disclosure of Q2 2026 results and full‑year outlook, influencing valuation of Nyxoah and peers in med‑tech.

03

What to watch

Potential reimbursement policy changes in 2027 could affect future revenue growth.

Relevance 7/10Novelty 8/10Timing: same‑day release on August 5, 2026

Background

Nyxoah SA, a medical‑technology firm listed on Nasdaq (NYXH), focuses on hypoglossal nerve stimulation for obstructive sleep apnea.

Company-level read

Ticker impact

$NYXHNeutralMedium confidence
Context

Nyxoah reported Q2 2026 results with €7.7M revenue, 22% sequential U.S. growth and full‑year guidance of €36‑40M, marking the first public disclosure of these numbers.

Expected impact

Potential modest upside on revenue beat, offset by higher expenses; price may trade within a narrow range.

Evidence & confidence

Strong top‑line growth signals demand, yet expanding SG&A and operating loss could limit upside until profitability improves.

Market effects

Sector

Highlights accelerating adoption of hypoglossal nerve stimulation devices in U.S. sleep‑apnea market.

Regional

Positive for European med‑tech exporters targeting U.S. reimbursement pathways.

Global

Shows growing demand for innovative sleep‑apnea therapies worldwide.

Counterpoint

What could challenge this read

Operating losses may deepen before scale economies materialize, suggesting caution.

Key entities

  • Executive
    Olivier Taelman

    Chief Executive Officer of Nyxoah, quoted on growth and financing.

Read at source← All news

Related articles

JUL 10
$NYXHMed

Nyxoah Touts Genio U.S. Launch Traction, Reimbursement Stability at Investor Day

Nyxoah SA said its Genio U.S. launch is gaining traction, citing 262 trained surgeons, 123 ordering customers, and 427 patients in prior authorization. It reported early launched accounts reached 15% market share in six months and said reimbursement is stable, with CMS code changes not affecting coverage and prior authorization approvals at a 100% rate. Nyxoah reiterated 2026 revenue guidance of EUR 36m to EUR 40m and noted a preliminary cash balance of EUR 98m.

yahoo.com4 min
JUL 7
$NYXHMed

Nyxoah Announces Preliminary Results for the Second Quarter of 2026

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) reported preliminary, unaudited Q2 2026 results: global net revenue expected at ~€7.7m (+21% sequential) and U.S. net revenue ~€5.2m (+22%). U.S. metrics included 55 surgeons trained and 89 new accounts activated. CMS proposed 12% hospital and 15% ASC reimbursement increases for Genio. Cash/assets expected ~€97.8m; €36m–€40m full-year guidance.

manilatimes.net6 min
JUN 10
$NYXHMedAI 8/10

Nyxoah Announces Closing of Underwritten Public Offering

Nyxoah SA said it has closed its previously announced underwritten U.S. public offering, selling 55,232,558 ordinary shares at $1.72 (EUR 1.48) each. Gross proceeds are about $95.0 million (EUR 81.9 million). Net proceeds will fund U.S. commercialization, Genio R&D and commercialization, and general corporate purposes; the company also plans to draw EUR 13.8 million from its EIB loan tranche in Q2 2026.

manilatimes.net4 min